Minimally-invasive varicose vein treatment further optimised through Radial® fibres by biolitec® – Excellent characteristics, perfect positioning and maximum efficiency of the laser beam – Treatment significantly more gentle – Hundreds of thousands of patients already treated with ELVeS®
Jena, February 7, 2012 – www.biolitec.de – With the development of the two novel fibres ELVeS Radial slim? and ELVeS Radial 2ring?, Jena-based biolitec® AG has set new standards in minimally-invasive laser therapy. The leader in this medical laser technology brings innovations to the market that will make the treatment of varicose veins even more precise, gentle and effective. Both fibre innovations open up a vast potential of specific new vein treatment optio
ns and thus make long-term treatments with all their side-effects and risks even less necessary than before.
The novel ELVeS Radial slim? fibre optimises the minimally-invasive intervention due to its extremely thin diameter. As a result, the fibre is extremely versatile and therefore suitable for more complicated anatomies, perforator veins and side branches. Recurrences after stripping treatments can be cured gently. The Radial 2ring? fibre splits the laser power into two phases by a distance of rings of 6mm. In this way energy density can be reduced at an unchanged power level which leads to a more homogeneous radiation within the vein. With their respective specific advantages, both fibre innovations contribute to fully realising the vast potential of endovenous vein laser treatments.
To physicians the new ELVeS Radial? fibres allow an even more precise mode of operation and a better control during the intervention. Dr. Wolfgang Neuberger, CEO of biolitec®, commented on the technological breakthrough: “We take the challenge to continually explore the boundaries of science and technology to deliver the next innovation in minimally-invasive procedures.” This strategy has already shaped the treatment options for varicose veins massively, and the new fibres will foster this process further: They emit laser energy 360°-radially and thereby provide for a homogeneous photothermic impact on the inner vein wall leading to even, effective and sustained closure of the vein. The radiation profile is optimal avoiding perforation of the sensitive surrounding tissue. In addition, the new design of the Radial 2ring? provides for an easier pullback technique.
The ELVeS Radial? intervention is conducted under local anaesthesia and the duration of the treatment is merely 30-45 minutes. Inpatient care is dispensable. The patient can get back to normal activities immediately and scarring is minimised.
Patients previously treated with the new ELVeS Radial? fibres reacted very positively to the treatment and report extraordinarily fast reconvalescence and good healing successes. The numerous advantages of the ELVeS® system already show in vast success in quantitative terms: Hundreds of thousands of patients already treated worldwide making ELVeS® the innovative treatment market leader in minimally-invasive solutions for varicose veins.
Dr. Neuberger, CEO of biolitec®: “We never stopped pioneering new endovenous laser treatments and never will.”
biolitec® AG worldwide is one of the leading companies in the field of medical laser treatment and the only provider that possesses all the relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PTD). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS® (Endo Laser Vein System) is the laser system most often used worldwide for the treatment of varicose veins, the Evolve? laser has established as gentle treatment in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics and ophtalmology as well as aesthetics also belong to the business field of biolitec®. biolitec® AG is listed in the Prime Standard and the German Entrepreneurial Index GEX® (ISIN DE0005213409). Further information at www.biolitec.de.
+49 (0) 69/959083-20
fr financial relations gmbh
+49 (0) 69 / 959083-20